Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Amgen Inc. is conducting a Phase 2a clinical study titled A Phase 2a, Open Label, Multicenter, Platform Trial to Assess the Safety, Tolerability, and Efficacy of Inebilizumab and Blinatumomab in Subjects With Autoimmune Diseases. The study aims to evaluate the safety and tolerability of two drugs, inebilizumab and blinatumomab, in adults with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). This research is significant as it addresses treatment options for these challenging autoimmune conditions.
The interventions being tested are inebilizumab, administered via intravenous infusion, and blinatumomab, given through subcutaneous injection. Inebilizumab is being tested in different doses for SLE with nephritis, while blinatumomab is being tested in various doses for SLE with and without nephritis and for RA.
The study follows a non-randomized, sequential intervention model with no masking, focusing primarily on treatment. This design allows for a structured assessment of each drug’s effects on the specified conditions.
The study began on August 22, 2024, with the latest update submitted on October 22, 2025. These dates are crucial as they indicate the study’s progression and the ongoing recruitment status, which is key for stakeholders monitoring the trial’s development.
The outcome of this study could significantly impact Amgen’s stock performance and investor sentiment, particularly if the results show positive advancements in treating SLE and RA. As autoimmune diseases are a competitive area in the pharmaceutical industry, successful results could position Amgen favorably against its competitors.
The study is currently recruiting, and further details can be accessed on the ClinicalTrials portal.